Topical analgesics for acute corneal pain: current options and emerging therapeutics

J Cataract Refract Surg. 2023 Nov 1;49(11):1160-1167. doi: 10.1097/j.jcrs.0000000000001225.

Abstract

Acute corneal pain is a common complaint that causes significant distress to patients and continues to challenge therapeutic avenues for pain management. Current topical treatment options have marked limitations in terms of both efficacy and safety, thus often prompting the adjunctive use of systemic analgesics, including opioids. In general, there have not been extensive advancements in pharmacologic options for the management of corneal pain over the past several decades. Despite this, multiple promising therapeutic avenues exist which hold the potential to transform the ocular pain landscape, including druggable targets within the endocannabinoid system. This review will summarize the current evidence base for topical nonsteroidal anti-inflammatory drugs, anticholinergic agents, and anesthetics before focusing on several potential avenues in the setting of acute corneal pain management, including autologous tear serum, topical opioids and endocannabinoid system modulators.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analgesics* / therapeutic use
  • Analgesics, Opioid
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Endocannabinoids* / therapeutic use
  • Humans
  • Pain / drug therapy
  • Pain Management

Substances

  • Endocannabinoids
  • Analgesics
  • Anti-Inflammatory Agents, Non-Steroidal
  • Analgesics, Opioid

Grants and funding